Short palate, lung and nasal epithelium clone 1 (SPLUNC1) is enriched in normal airway lining fluid, but is significantly reduced in airway epithelium exposed to a Th2
cytokine milieu. The role of SPLUNC1 in modulating airway allergic
inflammation (e.g., eosinophils) remains unknown. We used SPLUNC1 knockout (KO) and littermate wild-type (C57BL/6 background) mice and recombinant SPLUNC1
protein to determine the impact of SPLUNC1 on airway allergic/eosinophilic
inflammation, and to investigate the underlying mechanisms. An acute
ovalbumin (OVA) sensitization and challenge protocol was used to induce murine airway allergic
inflammation (e.g., eosinophils,
eotaxin-2, and Th2
cytokines). Our results showed that SPLUNC1 in the bronchoalveolar lavage fluid of OVA-challenged wild-type mice was significantly reduced (P < 0.05), which was negatively correlated with levels of lung eosinophilic
inflammation. Moreover, SPLUNC1 KO mice demonstrated significantly higher numbers of eosinophils in the lung after OVA challenges than did wild-type mice. Alveolar macrophages isolated from OVA-challenged SPLUNC1 KO versus wild-type mice had higher concentrations of baseline
eotaxin-2 that was amplified by LPS (a known risk factor for exacerbating
asthma). Human recombinant SPLUNC1
protein was applied to alveolar macrophages to study the regulation of
eotaxin-2 in the context of Th2
cytokine and LPS stimulation. Recombinant SPLUNC1
protein attenuated LPS-induced
eotaxin-2 production in Th2
cytokine-pretreated murine macrophages. These findings demonstrate that SPLUNC1 inhibits airway eosinophilic
inflammation in allergic mice, in part by reducing
eotaxin-2 production in alveolar macrophages.